Please use this identifier to cite or link to this item: https://scholarbank.nus.edu.sg/handle/10635/132812
DC FieldValue
dc.titleOTI-010 Osiris Therapeutics/JCR Pharmaceuticals
dc.contributor.authorTaupin, P.
dc.date.accessioned2016-12-13T05:36:49Z
dc.date.available2016-12-13T05:36:49Z
dc.date.issued2006-05
dc.identifier.citationTaupin, P. (2006-05). OTI-010 Osiris Therapeutics/JCR Pharmaceuticals. Current Opinion in Investigational Drugs 7 (5) : 473-481. ScholarBank@NUS Repository.
dc.identifier.issn14724472
dc.identifier.urihttp://scholarbank.nus.edu.sg/handle/10635/132812
dc.description.abstractOsiris Therapeutics is developing the donor-derived mesenchymal stem cell (MSC) therapy OTI-010, which repopulates the bone marrow stroma and thus supports engraftment of hematopoietic stem cells from the same donor. This stem cell therapy, which has been awarded Orphan Drug status, is currently in development for the potential enhancement of bone marrow transplants in cancer patients, for the prevention of graft versus host disease (GVHD), and for the treatment of Crohn's disease. Japanese licensee JCR Pharmaceuticals is investigating the therapy for the potential treatment of GVHD in patients undergoing bone marrow transplantation to treat leukemia. Phase II clinical trials in acute gastrointestinal GVHD and in adult and pediatric patients with treatment-refractory sever GVHD are currently underway. © The Thomson Corporation.
dc.sourceScopus
dc.typeArticle
dc.contributor.departmentOBSTETRICS & GYNAECOLOGY
dc.description.sourcetitleCurrent Opinion in Investigational Drugs
dc.description.volume7
dc.description.issue5
dc.description.page473-481
dc.description.codenCIDRE
dc.identifier.isiutNOT_IN_WOS
Appears in Collections:Staff Publications

Show simple item record
Files in This Item:
There are no files associated with this item.

Page view(s)

49
checked on Jan 26, 2023

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.